Hepion (HEPA) COO Sireesh Appajosyula Acquires 4M Shares

What Happened

• Sireesh Appajosyula, Chief Operating Officer of Hepion Pharmaceuticals (HEPA), reported acquisitions on 2026-08-03 totaling 4,000,000 shares.
• The filing shows a purchase of 2,000,000 common shares at $0.05 per share (cash paid = $100,000) and a second reported acquisition of 2,000,000 shares as a derivative transaction at $0.00 (no cash paid). Both entries are reported as Purchases (code P).
• Purchases are generally viewed as a more informative insider action than sales, but this report includes a derivative issuance that may reflect conversion, exercise, or another non-cash grant — the filing excerpt provided does not explain the mechanics.

Key Details

• Transaction date: 2026-08-03 (both entries).
• Report filed with SEC: 2026-08-12 — filed 9 days after the transaction (appears late relative to the usual 2-business-day Form 4 deadline).
• Prices/values: 2,000,000 @ $0.05 = $100,000 cash; 2,000,000 derivative @ $0.00 = $0 cash.
• Shares owned after transaction: not specified in the provided filing excerpt. Check the full Form 4 for "Amount of securities beneficially owned" fields.
• Notes: derivative acquisition reported at $0.00 — filing does not state whether this was an option exercise, conversion of convertible securities, restricted stock grant, or other issuance. No 10b5-1 plan or tax-withholding footnotes were provided in the summary supplied.

Context

• Derivative or zero-price acquisitions can result from exercises, conversions, or company issuances and may not require cash outlay; they can also cause dilution depending on the source. The filing excerpt here doesn’t specify the source, so consult the full Form 4 or related 8‑K for details.
• The transaction was reported late, which reduces the timeliness of the signal for investors; always verify the complete SEC filing for footnotes and issuer explanations before drawing conclusions.
• For retail investors: insider purchases can be a positive signal, but consider size relative to outstanding shares, reason for derivative issuance, recent corporate developments, and overall insider activity before acting.